Key Drivers
- Strong Cash Flow
- Rising Leverage
- Tight Liquidity
AIAI Summary
PTC is now a re-acceleration bet: investors should monitor whether ~9%–9.5% ARR growth and deferred ARR convert into fiscal-2027 revenue growth, as successful execution offers upside after the sell-off but another revenue miss could deepen the de-rating amid tighter liquidity and higher leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Rising Leverage
- •Tight Liquidity
PTC offers strong margins, cash generation, and cheaper valuation, but weakening profitability, tight liquidity, and rising leverage warrant close monitoring.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold rebound
- •Key resistance
PTC remains technically cautious after an 11.5% decline last month, with oversold RSI supporting a potential bounce but $128.72–$130.78 support and $141–$144 resistance key.
11.5% decline last month followed by a two-session rebound
Sentiment & News
Key News Insights:
- •ARR growth
- •Defense win
- •Clinical momentum
PTC Inc.'s sharp sell-off contrasts with improving ARR, guidance, and enterprise wins, while PTC Therapeutics adds positive clinical and pipeline catalysts.
PTC Inc. may offer a valuation-driven rebound opportunity, while PTC Therapeutics' outlook is supported by encouraging data and pipeline progress
Similar Companies in Technology
Other companies in the same sector with AI ratings